Osimertinib

Chemical formula: C₂₈H₃₃N₇O₂  Molecular mass: 499.619 g/mol  PubChem compound: 71496458

Therapeutic indications

Osimertinib is indicated for:

Non-small cell lung cancer with activating epidermal growth factor receptor mutations

Population group: only adults (18 years old or older)

Osimertinib as monotherapy is indicated for:

  • the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with activating epidermal growth factor receptor (EGFR) mutations.
  • the treatment of adult patients with locally advanced or metastatic EGFR T790M mutation-positive NSCLC.

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Adjuvant treatment after complete tumour resection in stage IB-IIIA non-small cell lung cancer

Population group: only adults (18 years old or older)

Osimertinib as monotherapy is indicated for the adjuvant treatment after complete tumour resection in adult patients with stage IB-IIIA non-small cell lung cancer (NSCLC) whose tumours have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations.

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Combination treatment of non-small cell lung cancer with epidermal growth factor receptor mutations

Population group: only adults (18 years old or older)

Osimertinib is indicated in combination with pemetrexed and platinum-based chemotherapy for the first-line treatment of adult patients with advanced NSCLC whose tumours have EGFR exon 19 deletions or exon 21 (L858R) substitution mutations.

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Contraindications

Osimertinib is contraindicated in the following cases:

Lactation

Lactation

St. John's Wort

Hypericum perforatum (St John's Wort)

Get recommendations

Factors such as age, gender, and health history are evaluated to create a personalized medication regimen.

Ask the Reasoner

Related medicines

Summary of Product Characteristics (SPC) 2024: TAGRISSO Film-coated tablet
< Previous: Overview
Next: Precautions >

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.

⇈